Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch Maintenance Combination Immunotherapy in Metastatic Pancreatic Cancer
NCT05419479Phase 2Suspended
- Start
- Nov 2022
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of domvanalimab, zimberelimab, sotigalimab in pancreatic cancer (PC). Started Nov 2022; status: suspended.
02
Drugs
domvanalimabzimberelimabsotigalimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05419479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419479.